Development of microRNA-based therapy for pancreatic cancer.
Development of microRNA-based therapy for pancreatic cancer.
复制标题
DOI：
10.1097/jp9.0000000000000029
复制
发表时间：
2019-12-01
期刊：
影响因子：
--
通讯作者：
Ju, Jingfang
中科院分区：
文献类型：
--
作者：
Fesler, Andrew;Ju, Jingfang
尽管在诊断和治疗方面进行了广泛的研究，但胰腺导管腺癌（PDAC）仍然是一种毁灭性疾病，是美国癌症相关死亡的第三大原因。对目前治疗方法的耐药性是胰腺癌患者生存率低的主要原因。为了克服这一重大挑战并改善患者预后，我们迫切需要新的治疗方法。PDAC耐药机制是复杂和多方面的。必须配备新的治疗方法来应对这一挑战。microRNA（miRNAs）由于其多靶向功能而成为填补这一角色的强有力候选者。miRNAs在胰腺癌耐药中具有重要作用。本文综述了与PDAC耐药机制相关的miRNA研究的最新进展，以及miRNA作为PDAC治疗药物的潜力。
Despite extensive research efforts on diagnosis and treatment, pancreatic ductal adenocarcinoma (PDAC) remains a devastating disease and the third leading cause of cancer-related death in the United States. Resistance to current therapeutic approaches is a major reason for the poor survival of pancreatic patients. In order to overcome this major challenge and improve patient outcomes, we are in desperate need of novel therapeutic approaches. PDAC chemoresistance mechanisms are complex and multifaceted. Novel therapeutics must be equipped to deal with this challenge. microRNAs (miRNAs) have emerged as strong candidates to fill this role due to their multitargeted function. miRNAs have been shown to have important roles in pancreatic cancer resistance. In this review, we summarize the recent advancement in miRNA research related to PDAC therapeutic resistance mechanisms and the potential of miRNAs as therapeutic agents for future clinical management of PDAC.